Table 2.
Genes/Molecular biomarkers | Characteristics | Imaging biomarkers | Number of studies | Ref |
EGFR | Diffusion | relative CBV, PSR | 10 | 13 |
Morphology | Anatomic location (radiogenomic maps) | 35, 36 | ||
Percentage of CE, NE, necrosis & oedema and largest diameter on lesion | 7 | |||
Morphology, diffusion & interaction with ECM | Border sharpness, restricted water diffusion, ADC | 37 | ||
Gene expressions | CE, necrosis, mass effect, oedema, cortical involvement, CE:N volume ratio, T2heterogeneity | 38 | ||
Infiltration, proliferation, neurogenesis and synaptic transmission | 39 | |||
Perfusion | VP & Ktrans | 40 | ||
Normalized CBV & CBF | 41 | |||
Mean & relative TBF | 42 | |||
MGMT methylation status | Perfusion | Ktrans | 5 | 43 |
Normalized CBV | 44 | |||
Morphology | Anatomic location | 35, 36 ] | ||
Textures | Correlation, energy, entropy & local intensity |
45 | ||
IDH1 | Morphology | Location | 4 | 35 |
Metabolite changes | Percentage of CE, NE, necrosis & oedema and largest diameter on lesion 2-hydroxyglutarate (2HG) |
7 [46, 47 |
||
Perfusion | TBF | 48 | ||
TP53 | Morphology | Percentage of CE, NE, necrosis & oedema and largest diameter on lesion | 2 | 7 |
Gene expressions | CE, necrosis, mass effect, oedema, cortical involvement, CE:N volume ratio, T2 heterogeneity | 38 | ||
PTEN loss | Morphology | Anatomic location | 2 | 36 |
Percentage of CE, NE, necrosis & oedema and largest diameter on lesion | 7 | |||
Ki-67 index | Diffusion, perfusion, metabolite change & genomics | relative CBF, FA, ADC, Cho/Cr, NAA/Cho, NAA/Cr, Lac/Cr & MI | 3 | 49, 50 |
Gene expressions | CE, necrosis, mass effect, oedema, cortical involvement, CE:N volume ratio, T2 heterogeneity | 38 | ||
VEGFR | Morphology and textural | Shape, texture, edge sharpness of necrotic core and surrounding CE rim | 2 | 51 |
Vascularization | CBV | 52 | ||
1p/19q codeletions | Vascularization | relative CBV | 1 | 53 |
GAP4 and WWTR1 genes | Intensities (ROI), sharpness of lesion boundaries, boundary shapes | Edge sharpness of necrotic portion | 1 | 18 |
HRAS copy number variation | Contrast enhancement and genetic expressions | Proportion of enhancing tumour & T1/FLAIR ratio | 1 | 8 |
Periostin and miR-219 | Cellular invasion | Edema/invasion FLAIR volumes | 1 | 54 |
Molecular subclasses of GBM | Hemodynamics | relative CBV | 1 | 52 |
ADC, apparent diffusion coefficient; CBF, cerebral blood flow;CBV, cerebral blood volume; CE, contrast enhancement; CE:N, contrast-enhancing volume to the necrotic tumour volume ratio; ECM, extra cellular matrix; EGFR,epidermal growth factor receptor; Cho, choline; Cr, creatine; FA, fractional anisotropy; IDH1,isocitrate dehydrogenase1; Ki-67antigen; Ktrans, volume transfer constant; Lac, lactate; MGMT, O6-methylguanine-DNA-methyltransferase; MI, myo-inositol; NAA, N-acetyl aspartate; NE, non-enhanced; PDGFA, platelet-derived growth factor; ROI, region of interest; PSR, percent signal recovery; PTEN, phosphatase and tensin homolog; TBF, tumour blood flow; TP53, tumour protein p53; VEGFR, vascular endothelial growth factor receptor; VP, plasma volume.